Metropolis Healthcare Ltd Q1 FY2024 Concall Summary

Key Takeaways

• Core business grew 12% YoY, but a government B2C contract masked it: Overall revenue declined 1% because a large one-off contract rolled off; the underlying B2C and B2B engine delivered double-digit growth on both volume and realization.
• Metropolis 3.0 sets a three-year expansion blueprint: The plan targets 700+ cities, 20–25% revenue from wellness, 40–45% from specialty testing, and 5–6 bolt-on acquisitions, all while stabilizing margins at pre-Covid levels.
• Network buildout is dilutive now but maturing fast: Labs opened in the last 15 months swung from negative 5% to positive 5% EBITDA margin, and management expects them to reach company-level margins within 24–36 months.
• Hitech integration is complete and already margin-accretive: The acquired asset grew double digits with margins slightly above the company average, and the Chennai-plus-Tamil Nadu rollout is accelerating with 50 new touchpoints planned this year.
• What to watch next quarter: Whether the seasonal Q2 uptick materializes as promised, the reclassification of 4–5 cities into the Focused portfolio, and any concrete adjacency plan for radiology.

Core Business & the B2C Contract Overhang

• 12% core growth, masked by a contract roll-off: Core business revenue (B2C plus B2B) rose 12% YoY, the fifth consecutive quarter of double-digit growth, but total reported revenue fell 1% because a large government B2C contract that had inflated the prior-year base did not repeat.
• Volume and realization both contributed: The 12% core growth split into 9% from volume and 3% from revenue per test and product mix, with a marginal ~1% benefit from price increases on specialized tests. Price corrections were taken on 25 routine tests in Delhi NCR to align with strategy.
• B2C led, even in mature markets: B2C revenue grew 13% YoY; Bombay, a mature market, grew over 15% with 10% volume growth and 5% RPT growth. Premium Wellness grew 27% YoY and now contributes 15% of overall revenue, up from 13%.
• B2B competition is easing: B2B revenue grew 9%, with faster growth coming from the stickier specialized segment. The competitive intensity in B2B has reduced, though it remains present.
• Seasonality explains the Q1 softness: Q1 is historically the slowest quarter because festivals, school holidays in West India, and weather patterns differ by region. Management expects Q2 and Q4 to be the strongest quarters for both revenue and profitability.

Ameera Shah: "we firmly believe that quarter 2 and quarter 4 will continue to be the strongest quarter for the year from the revenue and the profitability perspective. And we sort of stand by our comments and our commitment to get to sort of a similar margin profile as we were at last year, over the course of the year."

Metropolis 3.0: The Three-Year Strategic Plan

• Three pillars: Strengthen the core business, expand into adjacencies, and execute bolt-on acquisitions. The plan sets explicit three-year revenue-mix targets: 20–25% from wellness testing and 40–45% from specialty testing.
• Geographic ambition: Maintain leadership in West and South while aiming to be among the top 3 players in North and East. The city footprint is targeted to grow from 370 towns today to more than 700 cities in three years.
• Network expansion is front-loaded: The company added 6 labs and ~120 collection centres in Q1 and entered 70 new towns. For the remaining nine months of FY24, the target is 25 additional labs and ~700 centres, reaching 500 towns by year-end.
• Adjacencies are still undefined: Management is exploring basic radiology (ECG, X-Ray, sonography) as a capex-light adjacency but will return with a detailed plan only in coming quarters.
• Bolt-on M&A is aspirational but hard to execute: The plan calls for 5–6 acquisitions over three years, but management acknowledged that finding good-quality assets at reasonable valuations is "difficult to find, not easy." No acquisition budget was disclosed.

Ameera Shah: "It's very important to us that we buy assets that we believe are assets that we run clean and can be scaled up versus where you actually have to clean up huge number of skeletons in the closet and lose revenue and profit as a part of it."

Hitech Integration & Margin Delivery

• Integration is complete and synergies are flowing: Hitech has been fully integrated; cross-selling, upselling, and lab-operation merging are underway. Hitech revenue grew double digits in Q1 with margins slightly higher than the company-level EBITDA.
• No centre closures, but brand consolidation: Hitech's Bangalore and rest-of-Tamil Nadu businesses were merged with Metropolis brands, capturing lab and collection-centre synergies. Chennai continues to operate both brands separately.
• Expansion plan for the year: Hitech will add another 50 touchpoints across Chennai and the rest of Tamil Nadu, supported by targeted wellness campaigns, radiology cross-sell, B2C campaigns, digital marketing, and talent acquisition. No fixed COCO-vs-FOFO mix was given.

Network Economics & Margin Walk

• New labs are maturing on schedule: Labs opened in the last 15 months generated ₹7.38 crores in revenue in Q1 (3% of overall revenue) and reached 5% EBITDA margin, up from negative 5% in their first year. Labs opened in Q1 FY23 grew 270% in Q1 FY24. Management expects these labs to reach company-level EBITDA margin within 24–36 months of maturity.
• Dilution is quantified and steady: The dilution from network expansion will remain at 1.1% to 1.3% for the next two years.
• Cost control held despite investment: Costs grew only 1% YoY even as the company absorbed higher people costs, aggressive lab and network expansion, and increased marketing and digital spending.
• International business is a quiet contributor: The model mirrors India: 60–70% of testing is done locally, with 30–40% of samples sent to the global reference lab in Bombay for specialized work. Margins are similar to the group profile, and growth is slightly higher than India due to a smaller base. Management remains committed to organic international growth without major capital commitment.

City Classification & the B2C vs B2B Mix

• City categories are being redrawn: Management is actively considering reclassifying 4–5 additional cities into the Focused portfolio, with fresh B2C investments to follow. Some other cities will move into the Seeding category. The update is expected next quarter.
• Seeding Cities lag because they are B2B markets: Seeding Cities are primarily B2B markets that have faced competition, while Focused Cities are B2C markets where doctor and direct-to-consumer routes drive growth. A reported increase in the Seeding revenue proportion (from 21% to 23%) was a typographical error; the actual Seeding share is 18%, with Others at 23%.
• Wellness RPT declined on mix, not discounting: The drop in wellness revenue per test was driven by product mix: smaller markets get fewer tests at lower prices, which pulls down the overall RPT. It was not caused by increased discounting.

Ameera Shah: "what we always maintained was that if you have built a good quality business in pathology like Metropolis had, the digital competition would not have impacted you much because the customers who value their brand did not really value price and we're not the ones who are going to move to competitors for price benefit"

Guidance & Commitments

Key Metrics